Randomized trial · people

Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults on metformin, ecnoglutide lowered HbA1c about as well as dulaglutide over 32 weeks, and the effect lasted to 52 weeks.

Kind
Randomized trial
Studied in
People
Number studied
623
Published
2025
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether weekly ecnoglutide lowers blood sugar at least as well as weekly dulaglutide, and whether the 1.2 mg dose does better, in adults with type 2 diabetes on metformin.

How the study was done

A randomized, open-label phase 3 trial at 52 hospitals in China in 623 adults aged 18-75 with type 2 diabetes whose blood sugar stayed high on metformin alone. People were split evenly between weekly ecnoglutide 0.6 mg, ecnoglutide 1.2 mg, or dulaglutide 1.5 mg, and followed for 52 weeks, with the main result at week 32.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 32, HbA1c (a 3-month average of blood sugar) fell by 1.91% in the ecnoglutide 0.6 mg arm, 1.89% in the 1.2 mg arm, and 1.65% in the dulaglutide arm. Compared with dulaglutide, the difference was -0.26% for the 0.6 mg arm and -0.24% for the 1.2 mg arm (p=0.0002 for superiority). Both ecnoglutide doses met the bar for being no worse than dulaglutide, and the drops held through week 52. Over 52 weeks, 3% of the 0.6 mg arm, 4% of the 1.2 mg arm, and 3% of the dulaglutide arm stopped treatment because of side effects.

What it doesn’t show

Everyone knew which drug they got, and all sites were in China. The 1.2 mg arm's edge over dulaglutide was statistically significant, but the researchers judged it too small to matter clinically.

The paper

He et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025.

The compounds

More studies on Ecnoglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ecnoglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo